Literature DB >> 21912764

Estimating benefits of therapy in Crohn's disease in terms of indirect costs.

Subrata Ghosh.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21912764      PMCID： PMC3186724          DOI： 10.1155/2011/310417

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Authors:  Remo Panaccione; Edward V Loftus; David Binion; Kevin McHugh; Shamsul Alam; Naijun Chen; Benoît Guerette; Parvez Mulani; Jingdong Chao
Journal:  Can J Gastroenterol       Date:  2011-08       Impact factor: 3.522

2.  Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.

Authors:  C N Bernstein; N Papineau; J Zajaczkowski; P Rawsthorne; G Okrusko; J F Blanchard
Journal:  Am J Gastroenterol       Date:  2000-03       Impact factor: 10.864

Review 3.  How expensive is inflammatory bowel disease? A critical analysis.

Authors:  Selwyn Odes
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742
  3 in total
  1 in total

1.  Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A2 by Ethanol Extract of Boerhaavia diffusa L.

Authors:  Aladahalli S Giresha; Siddanakoppalu N Pramod; A D Sathisha; K K Dharmappa
Journal:  Pharmacognosy Res       Date:  2017 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.